Artificial intelligence is defined as the ability of computer systems to perform tasks that typically require human intelligence. Machine learning — a subset of AI — enables computers to learn from data without explicit programming. Recent advances in deep learning algorithms have generated substantial interest in medical applications, particularly in analysing complex genetic datasets. The convergence of AI and genomics is now widely regarded as one of the most consequential frontiers in modern biomedical science, promising to fundamentally reshape how we understand, predict, and prevent disease.
AI in Genomics: An Overview
The sequencing of the human genome opened a window into the molecular basis of health and disease, but the sheer volume and complexity of genomic data created an analytical bottleneck that traditional statistical methods struggled to resolve. A single human genome contains approximately three billion base pairs, and genome-wide association studies (GWAS) routinely generate datasets involving hundreds of thousands of genetic variants across tens of thousands of individuals. Machine learning models — particularly deep neural networks — are uniquely suited to this challenge: they can identify non-linear patterns across high-dimensional datasets, integrate multiple data modalities simultaneously, and improve in accuracy as more data becomes available. Projects such as DeepMind's AlphaFold, which achieved near-experimental accuracy in predicting protein structures from amino acid sequences, exemplify the transformative potential of applying deep learning to biological data at scale.
Identifying Disease Risk Factors with Machine Learning
One of the most direct clinical applications of AI in genetics is the identification of genetic variants associated with elevated disease risk. Polygenic risk scores (PRS) — which aggregate the effects of thousands of common genetic variants to estimate an individual's predisposition to conditions such as coronary artery disease, type 2 diabetes, and certain cancers — have been substantially improved through machine learning methods. Where classical GWAS analysis identifies variants one at a time under strict statistical thresholds, ML models can capture epistatic interactions (where the effect of one gene variant depends on the presence of another) that traditional approaches miss. Studies have shown that ML-enhanced PRS models outperform classical scores in stratifying patients by risk, potentially enabling earlier, more targeted interventions. Beyond polygenic conditions, deep learning applied to whole-genome sequencing data is being used to identify rare, high-impact mutations in individuals with undiagnosed rare diseases — dramatically reducing the diagnostic odyssey that previously took years or went unresolved.
Drug Target Discovery Powered by AI
The identification of new drug targets is another area where the AI-genetics intersection is yielding significant results. Historically, drug discovery has been slow, expensive, and characterised by high attrition rates — most compounds that enter development never reach clinical approval. By integrating genomic data with protein interaction networks, gene expression profiles, and clinical outcome data, AI systems can prioritise biological targets most likely to be causally relevant to disease and therapeutically tractable. Companies including Recursion Pharmaceuticals, BenevolentAI, and Insilico Medicine have developed AI-driven pipelines that have identified novel targets and repurposed existing compounds for new indications in fractions of the time and cost of conventional approaches. Notably, genetic validation — the principle that drug targets with genetic evidence of disease association have significantly higher clinical success rates — is now routinely incorporated into ML-driven target prioritisation frameworks, improving the quality of the candidates that enter the development pipeline.
Ethical and Practical Challenges
Despite its remarkable promise, the intersection of AI and genetics raises serious ethical and practical challenges that demand careful attention. Genetic data is among the most sensitive categories of personal information: it is immutable, inheritable, and capable of revealing not only an individual's health predispositions but also those of their biological relatives. The aggregation of large genomic datasets — necessary for training robust models — creates significant privacy risks, particularly as re-identification techniques grow more sophisticated. A further concern is representational bias: most large genomic datasets have historically overrepresented individuals of European ancestry, meaning that models trained on them perform less accurately for populations of African, Asian, or Indigenous descent. This disparity risks exacerbating existing health inequities unless addressed through deliberate and sustained investment in diverse data collection. Finally, the interpretability of deep learning models in genomics remains a challenge — clinicians and patients need to be able to understand and trust the basis for AI-generated risk predictions before those predictions can responsibly inform medical decisions.